{"id":"NCT01357356","sponsor":"Serenity Pharmaceuticals, Inc.","briefTitle":"Multicenter Study to Investigate SER120 Nasal Spray Formulations in Patients With Nocturia","officialTitle":"A Randomized, Double Blind, Placebo Controlled, Parallel Group, Multicenter Study to Investigate the Efficacy and Safety of SER120 Nasal Spray Formulations in Patients With Nocturia","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2011-05","primaryCompletion":"2012-10","completion":"2014-12","firstPosted":"2011-05-20","resultsPosted":"2020-10-08","lastUpdate":"2020-10-08"},"enrollment":750,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Nocturia"],"interventions":[{"type":"DRUG","name":"SER120 (750 ng/day)","otherNames":[]},{"type":"DRUG","name":"SER120 (1000 ng/day)","otherNames":[]},{"type":"DRUG","name":"SER120 (1500 ng/day)","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"SER120 (750 ng/day)","type":"EXPERIMENTAL"},{"label":"SER120 (1000 ng/day)","type":"EXPERIMENTAL"},{"label":"SER120 (1500 ng/day)","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to investigate the efficacy and safety of SER120 nasal spray formulations in patients with nocturia for a total duration of 14 weeks.","primaryOutcome":{"measure":"Change in # of Mean Nocturic Episodes Per Night","timeFrame":"12 weeks","effectByArm":[{"arm":"SER120 750 ng","deltaMin":-1.4,"sd":0.07},{"arm":"SER120 1000 ng","deltaMin":-1.4,"sd":0.07},{"arm":"SER120 1500 ng","deltaMin":-1.6,"sd":0.07},{"arm":"Placebo","deltaMin":-1.2,"sd":0.07}],"pValues":[]},"eligibility":{"minAge":"50 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":13},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":188},"commonTop":["Nasal discomfort","Headache","Hypertension"]}}